Search Results

A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (CLND6) (TORL123-002) MOA: TORL-1-23 is an ADC that targets CLDN6 and contains a MMAE payload. Key Eligibility Criteria: Histologically or cytologically confirmed diagnosis of advanced…

A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma MOA: Fianlimab (REGN3767) is an anti-LAG-3 monoclonal antibody. Cemiplimab (REGN2810) is an anti-PD-1 antibody. Key Eligibility Criteria: Histologically confirmed unresectable stage III and stage IV (metastatic) melanoma Uveal, acral or mucosal melanoma…

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (MK3475-587) Brief Summary: The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who…

Nadia Ashai, MD, is a fellowship-trained, board-certified medical oncologist and hematologist at Maryland Oncology Hematology. She earned her medical degree from the University of Maryland School of Medicine, followed by residency training at the University of Maryland Medical Center. She then completed a fellowship in oncology at the Albert Einstein College of Medicine, Montefiore Medical…

A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) MOA: Petosemtamab is a bispecific antibody targeting EGFR and LGR5 Key Eligibility Criteria: Metastatic or locally advanced HNSCC not amenable…